Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee.
Therapeutic advances in drug safety 2025 Gilmar Gutierrez, Gustavo Vazquez, Nisha Ravindran et al. 5 citations
Intranasal (IN) esketamine has become an effective and well-tolerated therapeutic option for the management of treatment-resistant depression within major depressive disorder (MDD-TRD). Despite these promising benefits, given the prevalence of ketamine abuse, concerns remain over the addiction liability that may be associated with esketamine treatment. The objective of this study is to assess...
DOI: 10.1177/20420986251347360 (opens in new tab)
Full text (opens in new tab)
Major depressive disorder
Abuse liability
Antidepressant effect
Ketamine abuse
+11